Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Seniors - 65 +
  • West Virginia
  • Morgantown


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com




Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • TMS for Post Stroke Depression
    NCT04093843
    Condition:   Post-stroke Depression
    Intervention:   Device: TMS
    Sponsor:   Amelia Adcock
    Recruiting
  • Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
    NCT03968809
    Condition:   Coronary Artery Disease
    Intervention:   Diagnostic Test: CardioFlux Magnetocardiography
    Sponsor:   Genetesis Inc.
    Recruiting
  • Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating Tumor Cells
    NCT03861598
    Conditions:   Glioblastoma Multiforme;   Glioblastoma
    Intervention:   Drug: Carvedilol
    Sponsors:   West Virginia University;   West Virginia Clinical and Translational Science Institute
    Recruiting
  • Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) Oximetry
    NCT03716193
    Conditions:   Skin Lesion;   Skin Cancer;   Skin Melanoma;   Tumor Skin
    Intervention:   Other: Oxygen
    Sponsors:   West Virginia University;   West Virginia Clinical and Translational Science Institute;   Mary Babb Randolph Cancer Center at West Virginia University Hospitals
    Recruiting
  • Use of Tele-Exercise for Translating an Evidence-Based Fall-Prevention Program for Older Adults in West Virginia
    NCT03714100
    Condition:   Accidental Falls
    Intervention:   Behavioral: Tai Ji Quan: Moving for Better Balance
    Sponsor:   West Virginia University
    Recruiting
  • Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity
    NCT04101721
    Condition:   Retinopathy of Prematurity
    Interventions:   Drug: aflibercept;   Procedure: laser photocoagulation
    Sponsor:   Regeneron Pharmaceuticals
    Recruiting
  • Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer
    NCT04024800
    Condition:   Triple-negative Breast Cancer
    Interventions:   Biological: AE37 Peptide vaccine;   Biological: Pembrolizumab
    Sponsors:   Antigen Express, Inc;   Merck Sharp & Dohme Corp.;   NSABP Foundation Inc
    Recruiting
  • Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
    NCT03914612
    Conditions:   Endometrial Clear Cell Adenocarcinoma;   Endometrial Dedifferentiated Carcinoma;   Endometrial Endometrioid Adenocarcinoma;   Endometrial Mixed Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Endometrial Undifferentiated Carcinoma;   Recurrent Endometrial Adenocarcinoma;   Recurrent Endometrial Carcinoma;   Recurrent Endometrial Clear Cell Adenocarcinoma;   Recurrent Endometrial Dedifferentiated Carcinoma;   Recurrent Endometrial Endometrioid Adenocarcinoma;   Recurrent Endometrial Mixed Cell Adenocarcinoma;   Recurrent Endometrial Serous Adenocarcinoma;   Recurrent Endometrial Undifferentiated Carcinoma;   Stage III Uterine Corpus Cancer AJCC v8;   Stage IIIA Uterine Corpus Cancer AJCC v8;   Stage IIIB Uterine Corpus Cancer AJCC v8;   Stage IIIC Uterine Corpus Cancer AJCC v8;   Stage IIIC1 Uterine Corpus Cancer AJCC v8;   Stage IIIC2 Uterine Corpus Cancer AJCC v8;   Stage IV Uterine Corpus Cancer AJCC v8;   Stage IVA Uterine Corpus Cancer AJCC v8;   Stage IVB Uterine Corpus Cancer AJCC v8
    Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Pembrolizumab;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
    NCT03662204
    Conditions:   Breast Cancer;   Lung Cancer;   Colorectal Cancer;   Prostate Cancer;   Bladder Cancer;   Uterine Cancer;   Kidney Cancer;   Renal Pelvis Cancer;   Pancreatic Cancer;   Liver Cancer;   Stomach Cancer;   Ovarian Cancer;   Esophageal Cancer
    Intervention:   Other: Blood Sample Collection
    Sponsor:   Exact Sciences Corporation
    Recruiting
  • Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    NCT02502266
    Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Ovarian Undifferentiated Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
    Interventions:   Drug: Cediranib;   Drug: Cediranib Maleate;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Questionnaire Administration;   Drug: Topotecan;   Drug: Topotecan Hydrochloride
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
    NCT02465060
    Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
    Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma
    NCT02972840
    Condition:   Lymphoma, Mantle Cell
    Interventions:   Drug: Acalabrutinib in combination with bendamustine and rituximab;   Drug: Placebo in combination with bendamustine and rituximab
    Sponsor:   Acerta Pharma BV
    Recruiting
  • Symptom Management Implementation of Patient Reported Outcomes in Oncology
    NCT03850912
    Conditions:   Other Cancer;   Gastrointestinal Cancer;   Thoracic Cancer;   Gynecologic Cancer
    Interventions:   Other: eSyM App Usage;   Other: SASS Questionnaire
    Sponsors:   Dana-Farber Cancer Institute;   National Cancer Institute (NCI);   RTI International;   Baptist Memorial Health Care Corporation;   Dartmouth-Hitchcock Medical Center;   Maine Medical Center;   West Virginia University;   Lifespan
    Recruiting
  • Clinical Trial of BP1001(Liposomal Grb2 Antisense Oligonucleotide) in Combination With Decitabine in AML / High Risk MDS
    NCT02781883
    Conditions:   Acute Myeloid Leukemia (AML);   High-risk Myelodysplastic Syndrome
    Intervention:   Drug: BP1001 in combination with decitabine
    Sponsor:   Bio-Path Holdings, Inc.
    Recruiting
  • A Phase 2a Diabetic Kidney Disease Study
    NCT04170543
    Condition:   Diabetic Kidney Disease
    Interventions:   Drug: MEDI3506;   Drug: Placebo
    Sponsor:   AstraZeneca
    Recruiting
  • A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD
    NCT03953079
    Condition:   Neovascular Age-Related Macular Degeneration
    Interventions:   Drug: Drug: GB-102;   Drug: Aflibercept
    Sponsor:   Graybug Vision
    Recruiting
  • Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
    NCT03937635
    Condition:   Smoldering Plasma Cell Myeloma
    Interventions:   Biological: Daratumumab;   Drug: Dexamethasone;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
    Recruiting
  • Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation
    NCT03930732
    Condition:   Chronic Obstructive Pulmonary Disease
    Interventions:   Drug: Dupilumab SAR231893;   Drug: Inhaled Corticosteroid;   Drug: Inhaled Long-Acting Beta Agonist;   Drug: Inhaled Long-Acting Muscarinic Antagonist;   Drug: Placebo
    Sponsors:   Sanofi;   Regeneron Pharmaceuticals
    Recruiting
  • OTO-313 in Subjects With Subjective Tinnitus
    NCT03918109
    Condition:   Tinnitus, Subjective
    Interventions:   Drug: OTO-313;   Drug: Placebo
    Sponsor:   Otonomy, Inc.
    Recruiting
  • Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
    NCT03904693
    Condition:   Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
    Interventions:   Drug: FDC macitentan/tadalafil;   Drug: Macitentan 10 mg;   Drug: Tadalafil 40 mg;   Drug: Placebo FDC;   Drug: Placebo macitentan;   Drug: Placebo tadalafil
    Sponsors:   Actelion;   Covance;   Almac Clinical Technologies;   WorldCare Clinical;   Frontier Science Foundation
    Recruiting
  • To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)
    NCT03894020
    Conditions:   Dry Age-related Macular Degeneration;   Macular Degeneration;   Retinal Disease;   Retinal Degeneration;   Geographic Atrophy;   Macular Atrophy
    Intervention:  
    Sponsor:   Gyroscope Therapeutics
    Recruiting
  • A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas and Participants With DLBCL
    NCT03467373
    Conditions:   B-Cell Lymphoma;   Non-Hodgkin Lymphoma
    Interventions:   Drug: RO7082859;   Drug: Obinutuzumab (G);   Drug: Rituximab (R);   Drug: Tocilizumab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section
    NCT03853694
    Conditions:   Elective Cesarean Section;   Pain Management
    Interventions:   Drug: 50 mcg Duramorph+ EXPAREL + multi-modal pain regimen;   Drug: 150 mcg Duramorph + multi-modal pain regimen;   Drug: Exparel TAP + multi-modal pain regimen
    Sponsor:   Pacira Pharmaceuticals, Inc
    Recruiting
  • Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients
    NCT03833154
    Condition:   Carcinoma, Non-Small-Cell Lung
    Interventions:   Drug: Durvalumab;   Other: Placebo
    Sponsor:   AstraZeneca
    Recruiting
  • Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)
    NCT03829319
    Condition:   Nonsquamous Non-small Cell Lung Cancer
    Interventions:   Biological: Pembrolizumab;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Pemetrexed;   Drug: Lenvatinib;   Drug: Placebo matching lenvatinib
    Sponsors:   Merck Sharp & Dohme Corp.;   Eisai Inc.
    Recruiting
  • Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC
    NCT03822351
    Conditions:   Stage III Non-small Cell Lung Cancer;   Unresectable
    Interventions:   Drug: Durvalumab + Oleclumab;   Drug: Durvalumab;   Drug: Durvalumab + Monalizumab
    Sponsor:   MedImmune LLC
    Recruiting
  • A Disease Registry of Patients With Mantle Cell Lymphoma
    NCT03816683
    Condition:   Mantle Cell Lymphoma
    Intervention:  
    Sponsor:   AstraZeneca
    Recruiting
  • Sleep for Stroke Management and Recovery Trial
    NCT03812653
    Conditions:   Ischemic Stroke;   Sleep Apnea;   Sleep Apnea, Obstructive;   TIA;   Stroke;   CPAP;   Telemedicine;   Home Sleep Apnea Test;   Randomized Clinical Trial;   Multicenter Trial
    Intervention:   Device: CPAP
    Sponsors:   University of Michigan;   National Institute of Neurological Disorders and Stroke (NINDS);   FusionHealth LLC;   Medical University of South Carolina;   University of Cincinnati
    Recruiting
  • Accelerated Hypofractionated or Conventionally Fractionated Radiotherapy and Durvalumab in Treating Patients With Stage II-III Non-small Cell Lung Cancer
    NCT03801902
    Conditions:   Lung Non-Small Cell Carcinoma;   PD-L1 Overexpression;   Recurrent Lung Carcinoma;   Stage II Lung Cancer AJCC v8;   Stage IIA Lung Cancer AJCC v8;   Stage IIB Lung Cancer AJCC v8;   Stage III Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8
    Interventions:   Biological: Durvalumab;   Radiation: Fractionated Stereotactic Radiation Therapy;   Radiation: Hypofractionated Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
    NCT03800134
    Condition:   Non-Small Cell Lung Cancer
    Interventions:   Drug: Durvalumab;   Other: Placebo;   Drug: Carboplatin/Paclitaxel;   Drug: Cisplatin/Gemcitabine;   Drug: Pemetrexed/Cisplatin;   Drug: Pemetrexed/Carboplatin
    Sponsor:   AstraZeneca
    Recruiting
  • An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis
    NCT03777436
    Condition:   Psoriasis
    Interventions:   Drug: Apremilast;   Other: Placebo
    Sponsor:   Celgene
    Recruiting
  • A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
    NCT03737851
    Condition:   Multiple Sclerosis (MS)
    Interventions:   Drug: elezanumab;   Drug: placebo
    Sponsor:   AbbVie
    Recruiting
  • A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis
    NCT03737812
    Condition:   Multiple Sclerosis (MS)
    Interventions:   Drug: elezanumab;   Drug: placebo
    Sponsor:   AbbVie
    Recruiting
  • Multi-arm Optimization of Stroke Thrombolysis
    NCT03735979
    Condition:   Acute Ischemic Stroke
    Interventions:   Drug: Argatroban;   Drug: Eptifibatide;   Drug: Placebo
    Sponsors:   University of Cincinnati;   National Institute of Neurological Disorders and Stroke (NINDS)
    Recruiting
  • AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment
    NCT03732794
    Conditions:   Atrial Fibrillation;   Persistent Atrial Fibrillation;   Longstanding Persistent Atrial Fibrillation
    Intervention:   Device: AtriCure CryoICE & AtriClip LAA Exclusion
    Sponsor:   AtriCure, Inc.
    Recruiting
  • Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy
    NCT03721172
    Condition:   Psoriasis
    Interventions:   Drug: Apremilast;   Other: Placebo
    Sponsor:   Celgene
    Recruiting
  • Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines
    NCT03716505
    Condition:   Migraine Disorders
    Interventions:   Device: gammaCore Sapphire active;   Device: gammaCore Sapphire Sham
    Sponsor:   ElectroCore INC
    Recruiting
  • Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
    NCT03712345
    Conditions:   Granulomatosis With Polyangiitis (GPA);   Microscopic Polyangiitis (MPA)
    Interventions:   Drug: IFX-1;   Drug: Placebo
    Sponsors:   InflaRx GmbH;   Iqvia Pty Ltd
    Recruiting
  • LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye
    NCT03711929
    Condition:   Non Infectious Uveitis
    Interventions:   Drug: DE-109 Intravitreal Injections;   Other: Sham Procedure
    Sponsor:   Santen Inc.
    Recruiting
  • ROMAN: A Study to Investigate the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer
    NCT03689712
    Condition:   Oral Mucositis
    Interventions:   Drug: GC4419;   Drug: Placebo
    Sponsor:   Galera Therapeutics, Inc.
    Recruiting
  • Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease
    NCT03664674
    Condition:   Meniere Disease
    Interventions:   Drug: OTO-104;   Drug: Placebo
    Sponsor:   Otonomy, Inc.
    Recruiting
  • A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)
    NCT03656536
    Conditions:   Unresectable Cholangiocarcinoma;   Metastatic Cholangiocarcinoma
    Interventions:   Drug: Pemigatinib;   Drug: Gemcitabine;   Drug: Cisplatin
    Sponsor:   Incyte Corporation
    Recruiting
  • Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer
    NCT03628066
    Condition:   Breast Cancer
    Interventions:   Drug: Letrozole;   Drug: Palbociclib;   Drug: Goserelin;   Diagnostic Test: Oncotype DX Breast Recurrence Score
    Sponsors:   NSABP Foundation Inc;   Genomic Health®, Inc.;   Pfizer
    Recruiting
  • Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.
    NCT03619213
    Condition:   Heart Failure With Preserved Ejection Fraction
    Interventions:   Drug: Dapagliflozin;   Drug: Placebo
    Sponsor:   AstraZeneca
    Recruiting
  • Dose Dense Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
    NCT03609216
    Conditions:   Infiltrating Bladder Urothelial Carcinoma;   Stage II Bladder Urothelial Carcinoma;   Stage III Bladder Urothelial Carcinoma
    Interventions:   Drug: Gemcitabine Hydrochloride;   Drug: Cisplatin;   Biological: Pegfilgrastim;   Procedure: Conventional Surgery;   Procedure: Radical Cystectomy;   Other: Chemoradiotherapy
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study)
    NCT03607838
    Condition:   Lumbar Disc Herniation
    Interventions:   Drug: SI-6603;   Drug: Sham injection
    Sponsor:   Seikagaku Corporation
    Recruiting
  • A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
    NCT03599713
    Condition:   Metastatic Merkel Cell Carcinoma
    Intervention:   Drug: INCMGA00012
    Sponsor:   Incyte Corporation
    Recruiting
  • Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND
    NCT03587805
    Condition:   Atopic Dermatitis
    Intervention:   Drug: Tralokinumab
    Sponsor:   LEO Pharma
    Recruiting
  • Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
    NCT03521934
    Condition:   Heart Failure-Type 2 Diabetes Mellitus
    Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo
    Sponsor:   Sanofi
    Recruiting
  • S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
    NCT03499808
    Conditions:   Amorphous, Eosinophilic, and Acellular Deposit;   Constipation;   Diarrhea;   Early Satiety;   Gastrointestinal Hemorrhage;   Hepatomegaly;   Lymphadenopathy;   Macroglossia;   Nausea;   Primary Systemic Amyloidosis;   Purpura;   Recurrent Primary Amyloidosis;   Refractory Primary Amyloidosis
    Interventions:   Biological: Isatuximab;   Other: Laboratory Biomarker Analysis
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
    NCT03445533
    Condition:   Metastatic Melanoma
    Interventions:   Drug: Ipilimumab;   Drug: IMO-2125
    Sponsors:   Idera Pharmaceuticals, Inc.;   Bristol-Myers Squibb
    Recruiting
  • Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
    NCT03433274
    Conditions:   Mitral Regurgitation;   Mitral Insufficiency;   Mitral Valve Insufficiency;   Cardiovascular Diseases;   Valve Disease, Heart;   Heart Valve Diseases;   Functional Mitral Regurgitation;   Degenerative Mitral Valve Disease
    Interventions:   Device: Tendyne Mitral Valve System;   Device: MitraClip System
    Sponsor:   Abbott Medical Devices
    Recruiting
  • A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04
    NCT03383146
    Conditions:   Gastroparesis;   Diabetes Mellitus
    Interventions:   Drug: Relamorelin;   Drug: Placebo
    Sponsor:   Allergan
    Recruiting
  • A Study to Quantify Use of Anticoagulation to Improve Management of Atrial Fibrillation
    NCT03382613
    Condition:   Atrial Fibrillation
    Intervention:  
    Sponsor:   Janssen Scientific Affairs, LLC
    Recruiting
  • Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
    NCT03377491
    Condition:   Pancreas Adenocarcinoma
    Interventions:   Device: NovoTTF-100L(P);   Drug: Gemcitabine;   Drug: nab paclitaxel
    Sponsor:   NovoCure Ltd.
    Recruiting
  • BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER
    NCT03371719
    Conditions:   PSA Progression;   Stage III Prostate Adenocarcinoma;   Stage IV Prostate Adenocarcinoma
    Interventions:   Drug: Apalutamide;   Radiation: External Beam Radiation Therapy;   Other: Placebo
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer
    NCT03367702
    Condition:   Stage II Prostate Adenocarcinoma
    Interventions:   Radiation: Intensity-Modulated Radiation Therapy (IMRT);   Radiation: Stereotactic Body Radiation Therapy (SBRT)
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)
    NCT03354273
    Condition:   Coronary Artery Disease (CAD)
    Interventions:   Drug: PET MPI;   Drug: SPECT MPI;   Drug: Pharmacological stress agents
    Sponsors:   GE Healthcare;   Pharmaceutical Product Development, LLC
    Recruiting
  • A Study to Test if Fremanezumab Reduces Headache in Patients With Posttraumatic Headache (PTH)
    NCT03347188
    Condition:   Post-Traumatic Headache
    Interventions:   Drug: Fremanezumab;   Drug: Placebo
    Sponsor:   Teva Branded Pharmaceutical Products, R&D Inc.
    Recruiting
  • A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
    NCT03323151
    Condition:   Mantle-Cell Lymphoma
    Interventions:   Drug: Ixazomib;   Drug: Ibrutinib
    Sponsors:   PrECOG, LLC.;   Takeda
    Recruiting
  • A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01
    NCT03285308
    Conditions:   Gastroparesis;   Diabetes Mellitus
    Interventions:   Drug: Relamorelin;   Drug: Placebo
    Sponsor:   Allergan
    Recruiting
  • Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo
    NCT03281954
    Condition:   Triple Negative Breast Cancer
    Interventions:   Drug: Placebo;   Drug: Atezolizumab
    Sponsors:   NSABP Foundation Inc;   Genentech, Inc.;   Hoffmann-La Roche
    Recruiting
  • Palbociclib in Real World Practice
    NCT03280303
    Conditions:   Advanced Breast Cancer;   Metastatic Breast Cancer
    Intervention:   Other: non-interventional
    Sponsor:   Pfizer
    Recruiting
  • A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
    NCT03274492
    Condition:   Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Polatuzumab Vedotin;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Vincristine Placebo;   Drug: Prednisone;   Drug: Polatuzumab vedotin Placebo
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
    NCT03258554
    Conditions:   Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Head and Neck Squamous Cell Carcinoma;   Hypopharyngeal Squamous Cell Carcinoma;   Laryngeal Squamous Cell Carcinoma;   Oral Cavity Squamous Cell Carcinoma;   Oropharyngeal Squamous Cell Carcinoma;   Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Squamous Cell Carcinoma of Unknown Primary;   Stage III Hypopharyngeal Carcinoma AJCC v8;   Stage III Laryngeal Cancer AJCC v8;   Stage III Lip and Oral Cavity Cancer AJCC v8;   Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8;   Stage IVA Hypopharyngeal Carcinoma AJCC v8;   Stage IVA Laryngeal Cancer AJCC v8;   Stage IVA Lip and Oral Cavity Cancer AJCC v8;   Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8;   Stage IVB Hypopharyngeal Carcinoma AJCC v8;   Stage IVB Laryngeal Cancer AJCC v8;   Stage IVB Lip and Oral Cavity Cancer AJCC v8;   Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
    Interventions:   Biological: Cetuximab;   Biological: Durvalumab;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group;   NRG Oncology
    Recruiting
  • Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
    NCT03233711
    Conditions:   Anal Basaloid Carcinoma;   Anal Canal Cloacogenic Carcinoma;   Anal Margin Squamous Cell Carcinoma;   Stage IIB Anal Cancer AJCC v8;   Stage IIIA Anal Cancer AJCC v8;   Stage IIIB Anal Cancer AJCC v8;   Stage IIIC Anal Cancer AJCC v8
    Interventions:   Biological: Nivolumab;   Other: Patient Observation
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer
    NCT03233191
    Condition:   Breast Screening
    Interventions:   Procedure: Digital Mammography;   Procedure: Digital Tomosynthesis Mammography;   Other: Laboratory Biomarker Analysis
    Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI);   Canadian Cancer Trials Group (CCTG)
    Recruiting
  • Thoracolumbar Burst Fractures Study Comparing Surgical Versus Non-surgical Treatment
    NCT02827214
    Condition:   Thoracolumbar Burst Fracture
    Intervention:  
    Sponsors:   AO Clinical Investigation and Documentation;   AOSpine International
    Recruiting
  • Paclitaxel, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Patients With Metastatic Breast Cancer
    NCT03199885
    Conditions:   Breast Adenocarcinoma;   Metastatic Breast Carcinoma;   Recurrent Breast Carcinoma;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Drug: Atezolizumab;   Drug: Paclitaxel;   Biological: Pertuzumab;   Other: Placebo;   Other: Quality-of-Life Assessment;   Biological: Trastuzumab
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
    NCT03137771
    Conditions:   Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
    Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy (3D-CRT);   Drug: Docetaxel;   Drug: Gemcitabine;   Radiation: Intensity-Modulated Radiation Therapy (IMRT);   Drug: Pemetrexed Disodium;   Radiation: Stereotactic Body Radiation Therapy (SBRT);   Drug: Erlotinib Hydrochloride;   Drug: Pembrolizumab
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • A Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989
    NCT03105102
    Condition:   Crohn's Disease
    Interventions:   Drug: placebo for risankizumab SC;   Drug: risankizumab IV;   Drug: placebo for risankizumab IV;   Drug: risankizumab SC
    Sponsor:   AbbVie
    Recruiting
  • MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
    NCT03072927
    Condition:   Lumbar Spinal Stenosis
    Intervention:   Device: MILD
    Sponsor:   Vertos Medical, Inc.
    Recruiting
  • Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
    NCT03070886
    Conditions:   Stage I Prostate Adenocarcinoma;   Stage II Prostate Adenocarcinoma;   Stage III Prostate Adenocarcinoma
    Interventions:   Drug: Bicalutamide;   Drug: Docetaxel;   Radiation: External Beam Radiation Therapy;   Drug: Flutamide;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Drug: Leuprolide Acetate;   Drug: Nilutamide
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery
    NCT03033576
    Conditions:   Advanced Melanoma;   Melanoma of Unknown Primary;   Mucosal Melanoma;   Refractory Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma;   Unresectable Melanoma
    Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
    NCT02997228
    Conditions:   Colorectal Adenocarcinoma;   Stage IV Colorectal Cancer AJCC v7;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVB Colorectal Cancer AJCC v7
    Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Fluorouracil;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
    NCT02997202
    Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: gilteritinib;   Drug: Placebo
    Sponsors:   Astellas Pharma Global Development, Inc.;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network
    Recruiting
  • Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
    NCT02947347
    Condition:   Treatment Naive Follicular Lymphoma
    Interventions:   Drug: ibrutinib;   Drug: placebo to match ibrutinib;   Drug: rituximab
    Sponsor:   Pharmacyclics LLC.
    Recruiting
  • Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
    NCT02927249
    Condition:   Node Positive HER2 Negative Breast Cancer
    Interventions:   Other: Placebo;   Drug: Aspirin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
    Recruiting
  • Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
    NCT02912559
    Conditions:   Colon Adenocarcinoma;   DNA Repair Disorder;   Lynch Syndrome;   Stage III Colon Cancer AJCC v7;   Stage IIIA Colon Cancer AJCC v7;   Stage IIIB Colon Cancer AJCC v7;   Stage IIIC Colon Cancer AJCC v7
    Interventions:   Drug: Atezolizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • NBP in Adult Patients With Acute Ischemic Stroke (AIS)
    NCT02905565
    Condition:   AIS
    Interventions:   Drug: NBP Softgel Capsules;   Drug: Placebo
    Sponsor:   CSPC-NBP Pharmaceutical Co., Ltd.
    Recruiting
  • Study Evaluating CERAMENT™|G in Open Diaphyseal Tibial Fractures
    NCT02820363
    Condition:   Tibial Fracture
    Interventions:   Device: CERAMENT|G;   Procedure: SOC treatment
    Sponsor:   BONESUPPORT AB
    Recruiting
  • Breast Cancer WEight Loss Study (BWEL Study)
    NCT02750826
    Condition:   Breast Carcinoma
    Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
    Recruiting
  • A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
    NCT02715284
    Condition:   Advanced or Metastatic Solid Tumors
    Intervention:   Biological: dostarlimab
    Sponsor:   Tesaro, Inc.
    Recruiting
  • Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy
    NCT02680184
    Condition:   Melanoma
    Interventions:   Drug: CMP-001;   Drug: Pembrolizumab
    Sponsor:   Checkmate Pharmaceuticals
    Recruiting
  • Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma
    NCT02654990
    Condition:   Multiple Myeloma
    Interventions:   Drug: panobinostat capsules;   Drug: bortezomib injection;   Drug: dexamethasone tablets
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Treating Patients With Limited Stage or Extensive Stage Small Cell Lung Cancer
    NCT02635009
    Conditions:   Extensive Stage Small Cell Lung Carcinoma;   Limited Stage Small Cell Lung Carcinoma
    Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Other: Cognitive Assessment;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
    Recruiting
  • Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension
    NCT02507687
    Conditions:   Glaucoma, Open-Angle;   Ocular Hypertension
    Interventions:   Drug: Bimatoprost SR;   Drug: Sham Bimatoprost SR;   Procedure: Selective Laser Trabeculoplasty;   Procedure: Sham Selective Laser Trabeculoplasty
    Sponsor:   Allergan
    Recruiting
  • RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
    NCT02489903
    Conditions:   Small Cell Carcinoma;   Carcinoma, Non-Small-Cell Lung;   Neuroendocrine Tumors;   Ovarian Epithelial Cancer
    Interventions:   Drug: RRx-001;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Carboplatin;   Drug: Irinotecan;   Drug: Vinorelbine;   Drug: Doxil;   Drug: Gemcitabine;   Drug: Taxane;   Drug: Paclitaxel;   Drug: Nab-Paclitaxel;   Drug: Pemetrexed
    Sponsor:   EpicentRx, Inc.
    Recruiting
  • Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
    NCT02488967
    Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
    NCT02466971
    Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Stage IB2 Cervical Cancer AJCC v6 and v7;   Stage II Cervical Cancer AJCC v7;   Stage II Vaginal Cancer AJCC v6 and v7;   Stage IIA Cervical Cancer AJCC v7;   Stage IIB Cervical Cancer AJCC v6 and v7;   Stage III Vaginal Cancer AJCC v6 and v7;   Stage IIIB Cervical Cancer AJCC v6 and v7;   Stage IVA Cervical Cancer AJCC v6 and v7;   Stage IVA Vaginal Cancer AJCC v6 and v7;   Vaginal Adenocarcinoma;   Vaginal Adenosquamous Carcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
    Interventions:   Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Internal Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Radiation: Radiation Therapy;   Drug: Triapine
    Sponsors:   National Cancer Institute (NCI);   NRG Oncology
    Recruiting
  • Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer
    NCT02364557
    Conditions:   Dyspnea;   Fatigue;   Nausea and Vomiting;   Pain;   Stage IV Breast Cancer
    Interventions:   Radiation: Stereotactic Radiosurgery;   Procedure: Therapeutic Conventional Surgery;   Other: Laboratory Biomarker Analysis
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Expanded Clinical Study of the Tendyne Mitral Valve System
    NCT02321514
    Condition:   Mitral Valve Regurgitation
    Intervention:   Device: Tendyne Mitral Valve System
    Sponsor:   Abbott Medical Devices
    Recruiting
  • Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
    NCT02224781
    Conditions:   Metastatic Melanoma;   Recurrent Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma
    Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
    NCT02194738
    Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Resectable Lung Non-Small Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
    NCT02193282
    Conditions:   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
    NCT02089217
    Condition:   Carotid Stenosis
    Interventions:   Procedure: Carotid endarterectomy (CEA);   Device: Carotid Stenting (CAS);   Other: Intensive Medical Management - no CEA;   Other: Intensive Medical Management - no CAS
    Sponsors:   Thomas G. Brott, M.D.;   National Institute of Neurological Disorders and Stroke (NINDS)
    Recruiting
  • Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma
    NCT02004275
    Condition:   Multiple Myeloma in Relapse
    Interventions:   Drug: pomalidomide;   Drug: ixazomib;   Drug: dexamethasone
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Celgene Corporation;   Millennium Pharmaceuticals, Inc.
    Recruiting
  • Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
    NCT01996865
    Condition:   Lymphoma, Non-Hodgkin
    Interventions:   Drug: Lenalidomide;   Drug: Rituximab
    Sponsor:   Celgene
    Recruiting
  • A Safety Study of SGN-LIV1A in Breast Cancer Patients
    NCT01969643
    Condition:   Breast Cancer
    Interventions:   Drug: SGN-LIV1A;   Drug: Trastuzumab
    Sponsor:   Seattle Genetics, Inc.
    Recruiting
  • Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
    NCT01896999
    Conditions:   Recurrent Classic Hodgkin Lymphoma;   Refractory Classic Hodgkin Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
    NCT01872975
    Conditions:   Stage IB Breast Cancer;   Stage II Breast Cancer
    Interventions:   Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
    Sponsors:   NSABP Foundation Inc;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
    Recruiting
  • A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
    NCT01848561
    Condition:   Ulcerative Colitis (UC)
    Intervention:  
    Sponsor:   AbbVie
    Recruiting
  • MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer
    NCT01805076
    Conditions:   Estrogen Receptor-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Triple-negative Breast Cancer
    Interventions:   Procedure: Breast surgery;   Procedure: Magnetic resonance imaging;   Procedure: Mammography
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   American College of Radiology Imaging Network
    Recruiting
  • Connect® MDS/AML Disease Registry
    NCT01688011
    Conditions:   Myelodysplastic Syndromes;   Acute Myeloid Leukemia
    Intervention:  
    Sponsor:   Celgene
    Recruiting
  • Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
    NCT00887146
    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Drug: concomitant temozolomide (TMZ);   Radiation: radiotherapy;   Drug: procarbazine;   Drug: adjuvant temozolomide (TMZ);   Drug: CCNU;   Drug: vincristine
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   European Organisation for Research and Treatment Center (EORTC);   Canadian Cancer Trials Group
    Recruiting
  • Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
    NCT00632853
    Condition:   Lung Cancer
    Interventions:   Radiation: Standard Radiation Dose Therapy;   Drug: cisplatin;   Drug: etoposide;   Radiation: High Radiation Dose Therapy;   Drug: carboplatin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • The Global cVAD Study
    NCT04136392
    Condition:   Cardiovascular Diseases
    Intervention:   Device: ABIOMED, Inc. hemodynamic support devices
    Sponsors:   Abiomed Inc.;   Beth Israel Deaconess Medical Center;   Yale University
    Recruiting
  • Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
    NCT03794349
    Conditions:   Ganglioneuroblastoma;   Recurrent Neuroblastoma;   Refractory Neuroblastoma
    Interventions:   Biological: Dinutuximab;   Drug: Eflornithine;   Drug: Irinotecan;   Biological: Sargramostim;   Drug: Temozolomide
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma
    NCT03769090
    Condition:   Asthma
    Interventions:   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg;   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg;   Combination Product: Albuterol sulfate metered-dose inhaler 180 μg
    Sponsor:   Bond Avillion 2 Development LP
    Recruiting
  • A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
    NCT03661866
    Conditions:   Atopic Dermatitis;   Alopecia;   Hidradenitis Suppurativa;   Vitiligo;   Psoriasis
    Intervention:  
    Sponsor:   Target PharmaSolutions, Inc.
    Recruiting
  • Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.
    NCT03529045
    Conditions:   Epilepsy;   Seizures;   Drug Resistant Epilepsy
    Intervention:   Device: Vagus Nerve Stimulation (VNS) Therapy
    Sponsor:   LivaNova
    Recruiting
  • Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
    NCT03493685
    Condition:   Focal Segmental Glomerulosclerosis
    Interventions:   Drug: sparsentan;   Drug: irbesartan
    Sponsor:   Retrophin, Inc.
    Recruiting
  • Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
    NCT03422822
    Condition:   Dermatitis, Atopic
    Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting
  • CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes
    NCT03350828
    Condition:   Cystic Fibrosis
    Intervention:  
    Sponsors:   Nicole Hamblett;   Cystic Fibrosis Foundation
    Recruiting
  • An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)
    NCT03339297
    Conditions:   Graft-versus-host Disease;   Acute-graft-versus-host Disease
    Interventions:   Drug: Defibrotide;   Drug: Standard of Care
    Sponsor:   Jazz Pharmaceuticals
    Recruiting
  • An Efficacy and Safety Study of SHP647 as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis
    NCT03290781
    Condition:   Ulcerative Colitis
    Interventions:   Drug: SHP647;   Other: Placebo
    Sponsor:   Shire
    Recruiting
  • A Safety Extension Study of SHP647 in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
    NCT03283085
    Conditions:   Crohn's Disease;   Ulcerative Colitis
    Interventions:   Drug: 25 mg SHP647;   Drug: 75 mg SHP647
    Sponsor:   Shire
    Recruiting
  • Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis
    NCT03259334
    Condition:   Ulcerative Colitis
    Interventions:   Drug: SHP647;   Other: Placebo
    Sponsor:   Shire
    Recruiting
  • A Study of AeroVanc for the Treatment of MRSA Infection in CF Patients
    NCT03181932
    Conditions:   MRSA;   Cystic Fibrosis
    Interventions:   Drug: Vancomycin inhalation powder;   Drug: Placebo inhalation powder
    Sponsor:   Savara Inc.
    Recruiting
  • A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease
    NCT03105128
    Condition:   Crohn's Disease
    Interventions:   Drug: placebo for risankizumab;   Drug: risankizumab IV;   Drug: risankizumab SC
    Sponsor:   AbbVie
    Recruiting
  • A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
    NCT03104413
    Condition:   Crohn's Disease
    Interventions:   Drug: placebo for risankizumab IV;   Drug: risankizumab SC;   Drug: risankizumab IV
    Sponsor:   AbbVie
    Recruiting
  • A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver (NAFL) or Nonalcoholic Steatohepatitis (NASH)
    NCT02815891
    Conditions:   Nonalcoholic Fatty Liver;   Nonalcoholic Steatohepatitis
    Intervention:  
    Sponsor:   Target PharmaSolutions, Inc.
    Recruiting
  • A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
    NCT02576431
    Condition:   Solid Tumors Harboring NTRK Fusion
    Intervention:   Drug: BAY2757556 (Larotrectinib, Vitrakvi)
    Sponsor:   Bayer
    Recruiting
  • A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.
    NCT01792726
    Condition:   Early Breast Cancer
    Intervention:   Radiation: Boost to the tumour bed
    Sponsors:   University College, London;   National Institute for Health Research, United Kingdom
    Recruiting
  • Neuropsychological and Behavioral Testing in Younger Patients With Cancer
    NCT00772200
    Conditions:   Childhood Malignant Neoplasm;   Cognitive Side Effects of Cancer Therapy
    Interventions:   Procedure: Cognitive Assessment;   Other: Quality-of-Life Assessment
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC